BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
MWN-AI** Summary
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a pioneer in regenerative medicine specializing in stem cell-based therapies, has announced its participation in the 2025 Maxim Growth Summit, scheduled for October 22-23 at The Hard Rock Hotel in New York City. During the event, CEO Lance Alstodt and Vice President of Research and Development Francisco Silva will engage in a panel discussion titled "Stem Cell Therapy – A Space That is Ready to have its Day," which will be moderated by Dr. Jason McCarthy from Maxim Group. Additionally, the company will conduct one-on-one meetings with institutional investors, although no webcast will be available due to the event format.
BioRestorative focuses on developing innovative therapeutic products utilizing adult stem cells through two main clinical programs: the Disc/Spine Program and the Metabolic Program. The lead candidate in the Disc/Spine Program, BRTX-100, addresses painful lumbosacral disc disorders using mesenchymal stem cells extracted from the patient’s own bone marrow. BRTX-100 aims to provide non-surgical relief for patients suffering chronic lower back pain and has recently commenced a Phase 2 clinical trial, supported by clearance from the FDA to research its efficacy in treating chronic cervical discogenic pain.
In the Metabolic Program, BioRestorative is developing therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells (BADSC). Initial research suggests that enhanced brown fat levels can promote calorie burning and reduce glucose and lipid levels, potentially impacting obesity-related health risks.
Additionally, the company operates a BioCosmeceutical platform, focusing on a proprietary serum designed to reduce fine lines and improve skin appearance, with plans for further product development in the aesthetic space.
MWN-AI** Analysis
As BioRestorative Therapies, Inc. prepares to participate in the 2025 Maxim Growth Summit, investors should consider several factors that may influence the company's stock performance and prospects in the regenerative medicine sector.
BioRestorative focuses on stem cell-based therapies, an area poised for significant growth given the increasing demand for non-invasive treatment options for degenerative diseases. Their flagship product, BRTX-100, targeting chronic lower back pain, is currently in Phase 2 clinical trials, and holds promise with its innovative approach leveraging autologous stem cells. Furthermore, with FDA clearance for investigating cervical pain, the potential for market traction is high if clinical outcomes support its efficacy.
Additionally, the metabolic program utilizing brown adipose derived stem cells represents a unique angle in combating obesity and related metabolic disorders. If successful, these therapies could tap into a vast market, given the global rise in obesity and the accompanying healthcare costs. Market studies suggest growing interest in effective treatment solutions, and BioRestorative’s focus on research in this realm could catalyze growth and capture investor attention.
The BioCosmeceuticals platform adds another dimension to their portfolio, addressing the burgeoning cosmetic market with its proprietary biologic serum designed to reduce aging signs. This strategic diversification could bolster revenue streams and stabilize financial performance, particularly if they successfully navigate the regulatory landscape for new products.
Investors should also remain cognizant of the risks associated with biotech investments, particularly in clinical trials and regulatory approvals. However, the upcoming summit provides a vital opportunity for management to directly engage with institutional investors, potentially enhancing market confidence in the company’s direction.
Overall, with accompanying clinical milestones and product pipeline developments, BioRestorative Therapies presents an intriguing investment opportunity for those willing to engage with high-risk, high-reward ventures in the biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit , taking place from October 22nd to 23rd at The Hard Rock Hotel NYC.
Lance Alstodt, BioRestorative’s CEO, and Francisco Silva, the Company’s Vice President of Research and Development, will be participating in a panel titled “Stem Cell Therapy – A Space That is Ready to have its Day,” to be moderated by Jason McCarthy, Ph.D., Maxim Group’s Senior Managing Director, Head of Biotechnology Research.
BioRestorative management will also be meeting with institutional investors in a one-on-one format during the event. Due to the format of the event, no webcast will be available.
About BioRestorative Therapies, Inc.
BioRestorative ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC ™ ): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem ® ): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ**
How does BioRestorative Therapies Inc. (BRTX) plan to differentiate its BRTX-100 therapy from existing non-surgical treatments for disc/spine disease during the upcoming 2025 Maxim Growth Summit?
What specific metrics or milestones will BioRestorative Therapies Inc. (BRTX) present to institutional investors at the 20Maxim Growth Summit regarding the progress of its Phase 2 clinical trial for BRTX-100?
In the context of the upcoming panel discussion, what challenges does BioRestorative Therapies Inc. (BRTX) foresee in the stem cell therapy market, and how does the company plan to navigate these challenges?
Can BioRestorative Therapies Inc. (BRTX) provide updates on its commercial BioCosmeceutical platform and the potential expansion into new products during the 2025 Maxim Growth Summit?
**MWN-AI FAQ is based on asking OpenAI questions about BioRestorative Therapies Inc (NASDAQ: BRTX).
NASDAQ: BRTX
BRTX Trading
-2.26% G/L:
$0.2901 Last:
1,689,480 Volume:
$0.3074 Open:
